VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives $0.95 Consensus Target Price from Analysts

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been assigned a consensus rating of “Reduce” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $0.95.

A number of equities research analysts have recently commented on the stock. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st. Stifel Nicolaus cut shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a research note on Wednesday, December 17th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $0.90 price target (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th.

VistaGen Therapeutics Price Performance

VTGN opened at $0.57 on Friday. The firm has a market cap of $22.56 million, a P/E ratio of -0.30 and a beta of 0.29. The business’s fifty day simple moving average is $0.59 and its 200 day simple moving average is $2.26. VistaGen Therapeutics has a 52 week low of $0.43 and a 52 week high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.14 million. As a group, equities analysts expect that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Trading of VistaGen Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in VistaGen Therapeutics in the 4th quarter valued at about $25,000. Cubist Systematic Strategies LLC purchased a new position in VistaGen Therapeutics during the first quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of VistaGen Therapeutics in the 3rd quarter valued at $39,000. Seven Fleet Capital Management LP purchased a new stake in shares of VistaGen Therapeutics during the 4th quarter valued at $42,000. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of VistaGen Therapeutics during the 4th quarter worth $50,000. 78.39% of the stock is owned by institutional investors and hedge funds.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.